Impact of Target‐Mediated Elimination on the Dose and Regimen of Evolocumab, a Human Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)

Understanding the pharmacokinetic (PK) and pharmacodynamic (PD) relationship of a therapeutic monoclonal antibody against proprotein convertase subtilisin/kexin type 9 (PCSK9) exhibiting target‐mediated drug disposition (TMDD) is critical for selecting optimal dosing regimens. We describe the PK/PD...

Descripción completa

Detalles Bibliográficos
Autores principales: Gibbs, John P., Doshi, Sameer, Kuchimanchi, Mita, Grover, Anita, Emery, Maurice G., Dodds, Michael G., Gibbs, Megan A., Somaratne, Ransi, Wasserman, Scott M., Blom, Dirk
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Pharmacokinetics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5412926/
https://www.ncbi.nlm.nih.gov/pubmed/27861991
http://dx.doi.org/10.1002/jcph.840

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5412926/
https://www.ncbi.nlm.nih.gov/pubmed/27861991
http://dx.doi.org/10.1002/jcph.840

Ejemplares similares